Skip to main content

ADVERTISEMENT

P2Y12 Inhibitors

10/06/2019
Think of the P2Y12 receptor as being shaped like a crown. If you drop a ball into the central part of the crown, that is the ADP site of the receptor. Clopidogrel, prasugrel, and cangrelor occupy that central site. Ticagrelor, however, is a...
Think of the P2Y12 receptor as being shaped like a crown. If you drop a ball into the central part of the crown, that is the ADP site of the receptor. Clopidogrel, prasugrel, and cangrelor occupy that central site. Ticagrelor, however, is a...
Think of the P2Y12 receptor as...
10/06/2019
Cath Lab Digest
09/05/2019
We compared patients with coronary artery disease who underwent PCI having received either scheduled, planned tirofiban with short-term infusion or planned bivalirudin, which most of the time was without any use of a GP IIb/IIIa receptor...
We compared patients with coronary artery disease who underwent PCI having received either scheduled, planned tirofiban with short-term infusion or planned bivalirudin, which most of the time was without any use of a GP IIb/IIIa receptor...
We compared patients with...
09/05/2019
Cath Lab Digest
02/03/2019
The ongoing opioid crisis in this country, along with the judicial use of morphine in patients with acute coronary syndrome, have created an environment where it is important to bring awareness to physicians and medical staff about morphine,...
The ongoing opioid crisis in this country, along with the judicial use of morphine in patients with acute coronary syndrome, have created an environment where it is important to bring awareness to physicians and medical staff about morphine,...
The ongoing opioid crisis in...
02/03/2019
Cath Lab Digest
Original Contribution
10/15/2018
Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...
Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...
Pretreatment with P2Y12...
10/15/2018
Journal of Invasive Cardiology